Quince Therapeutics (QNCX) Stock Surges 300% on Strategic Review Announcement
Quince Therapeutics saw its stock price explode by over 300% in a single trading session after disclosing plans to explore strategic alternatives. The biotech firm has engaged LifeSci Capital as its exclusive financial advisor to evaluate potential partnerships, joint ventures, or M&A opportunities.
Trading volume surpassed 1.1 billion shares as market participants speculated about a potential premium buyout. While the company cautioned that no transaction is guaranteed, the market reaction reflects Optimism about unlocking shareholder value through strategic deals.
The company specializes in bone-targeted drug delivery platforms for rare disease treatments. This technical approach in biotherapeutics appears to have attracted speculative interest despite the inherent risks in micro-cap biotech investments.
